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Abstract
Background: Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk factors. Controlling
these factors requires lifestyle modifications alongside utilisation of anti-diabetic medications. Different glucose lowering [(biguanides (BIGs), sulfonylureas (SUAs), thiazolidinediones (TNZ)], lipid lowering (statins), and anti-hypertensive
medicines [angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers (CCBs), angiotensin II receptor
blockers (ARBs) and central acting drugs (CADs)] have been approved for controlling hyperglycaemia, dyslipidaemia
and hypertension respectively. Here, we examined factors that characterise T2DM and explored the response to medication therapy among T2DM patients.
Methods: This prospective cohort study recruited 241 T2DM patients reporting at a clinic in Ghana, from January
through to August, 2016. Each patient’s demographic, medications and anthropometric data was obtained while
information on medication adherence was captured using Morisky adherence scale-8 (MMAS-8). Fasting blood samples were collected for biochemical analysis.
Results: The mean age of participants was 57.82 years for baseline and six-month follow-up. Physical activity differed
at baseline and follow up (p < 0.05) but not body mass index (BMI). BIG alone, or in combination with SUA and TNZ
did not improve glycaemic status at follow up (p > 0.05). Many participants using either ACEI or ARB were able to control their blood pressures. Among dyslipidaemia patients under statin treatment, there was an improved lipid profile
at follow-up.
Conclusions: Statin medications are effective for reducing dyslipidaemia in T2DM patients. However, control of
modifiable risk factors, particularly blood glucose and to a lesser degree blood pressure is suboptimal. Addressing
these will require concomitant interventions including education on medication adherence and correct dietary plans,
lifestyle modifications and physical activity.
Keywords: Type II diabetes mellitus, Hypertension, Anti-diabetic medications, Risk factors, Ghana
Background
Despite substantial efforts, type II diabetes mellitus
(T2DM) remains a major contributor to the world’s
*Correspondence: wei.wang@ecu.edu.au
1
School of Medical and Health Sciences, Edith Cowan University, 270
Joondalup Drive, Joondalup, Perth 6027, WA, Australia
Full list of author information is available at the end of the article

morbidity and mortality [1, 2]. In 2014 alone, more
than 2.2 million people died from the disease and at
approximately the same time, nearly 415 million adults
were affected worldwide, representing a prevalence
rate of ≈8.5% [2, 3]. This prevalence rate is expected to
translate into 439 million T2DM cases by 2030 [3, 4].
Unfortunately, countries with less healthcare resources
such as those in sub-Saharan Africa (SSA) are among
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the most affected with some 14.2 million people presently suffering from the disease [2]. For example, in
Ghana, T2DM affected more than 266,200 individuals
at a prevalence rate of 6% in 2015, and it is presently
ranked among the top 10 causes of all adult deaths [2,
5].
People with T2DM have an increased risk of developing many health problems such as cardiovascular diseases [6, 7], amputations [8], depression [9, 10], and
cognitive impairment [11–14]. Moreover, prolonged
hyperglycaemia is strongly linked with many microvascular and, to a lesser extent, macrovascular complications
and premature mortality [15]. In fact, just a 1% rise in
glucose level will lead to an 18% increased risk for cardiovascular events [16], 37% increased risk for renal diseases
[11] and 12–14% increased risk for premature mortality
[11, 15, 16].
Additionally, the majority of T2DM patients are physically inactive which has led to dyslipidaemia, obesity
and hypertension [17, 18]. These in turn lead to further
consequences. Studies have shown that obesity accounts
for 14% of all adult deaths while hypertension alone is an
independent risk factor for cognitive decline [19], renal
dysfunction [20, 21] and ultimately responsible for 45% of
all deaths. Therefore, given these detrimental outcomes,
controlling known modifiable factors should be a priority.
It has long been documented that achieving good glycaemic levels is pivotal to delaying T2DM complications. According to the American Diabetes Association
(ADA), reduction of microvascular and macrovascular
complications is possible at HbA1c <7% [22]. This could
be achieved with single, combination or multiple glucose
lowering medications [23, 24].
Alongside maintaining normal glycaemic levels, therapeutic interventions should be extended to other concomitant factors such as dyslipidaemia, hypertension
and obesity [25, 26]. Different lipid lowering and antihypertensive medicines have been approved for controlling dyslipidaemia and hypertension respectively;
majority of which are currently available in Ghana
[5, 26]. Yet, the control of T2DM modifiable factors
has been suboptimal, partly because studies to create
awareness of T2DM are generally scarce in this region.
Moreover, these studies have mainly been cross-sectional providing limited information on association or
causality. Therefore, in this study, we explored the manifestations and the associated factors that characterise
T2DM in a longitudinal design. Additionally, this study
highlights the proportion of T2DM patients that have
good glycaemic control, blood pressure and lipid levels
and addresses the factors that contribute to poor management and control of these modifiable risk factors.
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Methods
Study design

This prospective cohort study was conducted at the diabetic clinic of the Komfo Anokye Teaching Hospital
(KATH) from January through to August 2016. In all, 241
participants with T2DM aged 35–70 years who reported to
the clinic for review and medications were recruited. The
study protocol was reviewed by the Committee on Human
Research, Publication and Ethics (CHRPE), Kwame Nkrumah University of Science and Technology (KNUST),
Kumasi and the Human Research Ethics Committee
(HREC), Edith Cowan University (ECU), Australia. Written
informed consent was obtained from each participant.
Inclusion and exclusion criteria

The study included only those who were diagnosed as
having T2DM, based on the international classification
of diabetes (ICD 10) criteria. Participants who were taking insulin injections were assumed to be suffering from
type I diabetes mellitus and therefore were excluded.
Additionally, among the original 260 T2DM participants
recruited for the study, 19 were excluded, mainly because
of missing clinical data.
Anthropometric and blood pressure measurements

After obtaining demographic data and information on
the general health status from each participant, information of medication adherence was obtained using the
validated Morisky Adherence Scale-8 (MMAS-8). This
questionnaire comprises 8 items and responses for item 1
through 7 are either ‘yes’ or ‘no’ whereas item 8 comprises
a 5-point Likert scale [27]. Following this, anthropometric measurements were taken. Weight (kg) and height
(cm) were measured with a standard stadiometer (SECA,
Hamburg, Germany). These were used to determine the
body mass index (BMI), calculated as BMI = weight (kg)/
height (m)2. Waist and hip circumference were measured
in cm using a tape measure and waist-to-hip ratio (WHR)
was calculated as WHR = waist (cm)/hip (cm). Systolic
blood pressure (SBP) and diastolic blood pressure (DBP)
were measured using a standard sphygmomanometer
(Omron HEM711DLX, UK). To assess the level of physical activity, we asked basic questions such as 1) what is
the level of physical activity during the last 7 days?, 2) on
how many days did you walk for at least 10 min at a time
in your leisure time?
Blood sample collection and biochemical assay

Venous fasting blood samples were collected from
each participant into tubes containing EDTA (ethylene
diamine tetraacetic acid), fluoride oxalate and gel separator. Fasting plasma glucose (FPG) in fluoride tubes
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and glycated haemoglobin (HbA1c) in EDTA tubes were
measured on an automated chemistry analyser (Roche
Diagnostics, COBAS INTEGRA 400 Plus, USA). Similarly, serum total cholesterol (TC), high density lipoprotein cholesterol (HDL-c), low density lipoprotein
cholesterol (LDL-c), and triglycerides (TG) were measured on the automated chemistry analyser (Roche Diagnostics, COBAS INTEGRA 400 Plus, USA). Non-HDL
was calculated as Non-HDL = total cholesterol-HDL.
Coronary risk ratio and very low density lipoprotein
(VLDL) cholesterol were calculated on the automated
chemistry analyser. Various medications utilised by the
T2DM patients at the clinic are shown in Fig. 1.
Definition of terms

Lipid lowering

Blood pressure
lowering

Glucose lowering

High plasma glucose; FBG >7 mmol/L, HbA1c >7.2%
[28].
Normal BP; 140/90 mmHg, high SBP >140 mmHg,
high DBP >90 mmHg [29].
Dyslipidaemia: waist circumference ≥102 cm (males),
≥88 cm (females), WHR >90 (men) and 0.85 (female).
High TG ≥1.7 mmol/l, HDL-C <1.0 (male), 1.03 (female),

high LDL-C ≥2.59 mmol/l, high total cholesterol
≥5.18 mmol/l, high non-HDL ≥3.37 mmol/l [30].
Statistical analysis

Normality distribution was checked by the Shapiro–Wilk
test. All continuous data was recorded as mean ± standard deviation and as frequency (percentages) for categorical variables. Between group comparisons for continuous
variables were performed using student t-tests, and intergroup comparisons of categorical variables were performed using Chi square tests. Association between
categorical variables and FBG or HbA1c were performed
using logistic regression models and odds ratios (ORs)
at 95% confidence intervals (95% CI) were recorded. All
statistical analyses were performed using the Statistical
Package for Social Sciences (SPSS), version 22. A p < 0.05
was considered significant.

Results
Among the study population, the male to female ratio
was 99/142 at baseline and 66/94 at follow up respectively. BMI and WHR of participants did not significantly

Biguanides

Sulfonylureas

Thiazolidinediones

Meormin

Gliclazide
Glimeperide
Glibenclamide

Glizone
Pioglitazone

Angiotensin
converng enzyme
inhibitors

Central acng
drugs

Angiotensin
receptor
antagonist

Calcium channel
blockers

Losartan

Aldomet
Hydralazine

Lisinopril

Nifecard
Nifedipine
Amlodipine

Stans

Fig. 1 Category of medications utilised by T2DM patients

Atorvastan

Other common drugs
Omiprazole
Bendoflurozide
Asprin
Carbamazipine
Tegretol
Tramadol
Cefuroxime
Zincovit
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differ from baseline to follow up [i.e. (p = 0.172) and
(p = 0.276) respectively]. However, there was a significant difference in levels of physical activity from baseline
to 6-month follow up (p = 0.0001) (Table 1).
The majority of the study participants were aged
51–60 years [81 (33.6%) vs 55 (34.4%)] while the lowest age range was 31–40 years [14 (5.8%) vs 10 (6.3%)]
(Table 2). The severity and mean levels of the measured
parameters were not significantly different from baseline to follow-up; [SBP (p = 0.474 and p = 0.600), DBP
(p = 0.382 and p = 0.620), FBG (p = 0.364 and p = 0.940),
TC (p = 0.328 and p = 0.160), non-HDL (p = 0.270
and p = 0.250) and LDL-c (p = 0.092 and p = 0.430)].
However, there was a difference in the severity and
mean levels of HbA1c [(p = 0.004 and p = 0.0001)], TG
[(p = 0.006 and p = 0.0001)] and HDL-c [(p < 0.0001 and
p = 0.0001)] from baseline to follow up (Table 2).
After adjusting for age and medication use, high BMI,
SBP, DBP, TC, TG, HDL, non-HDL-c, and LDL-c status
were not significant independent risk factors for high
FBG in both baseline and follow up groups (p > 0.05)
(Table 3). Similarly, in the logistic regression model,
increased SBP, DBP, TC and non-HDL were slightly

associated with high HbA1c levels at both baseline and
follow up but not significantly (p > 0.05) (Table 4).
From baseline to follow up, FBG levels increased by
25.0% when (BIG) was administered alone. In a combination therapy with either SUA or TNZ, there was only
a decrease in FBG levels by 1% (p = 0.9924) and 1.6%
(p = 0.1098) respectively. However, FBG levels decreased
by 15.8% when all three medications; BIG, SUA and
TNZ were administered (p = 0.216). Meanwhile, levels
of HbA1c were increased by 29.6% after BIG treatment
alone (p = 0.0094), increased by 19.2% and 16.7% when
BIG was combined with SUA (p = 0.0175) and TNZ
(p = 0.0903) respectively. However, a multiple therapy
of BIG, SUA and TNZ resulted in only a 1.3% increase of
HbA1c levels (p = 0.8308) (Table 5).
There was a mean percentage decrease effect in levels of HDL-c (p < 0.0001), TG (p = 0.0259) and VLDL-c
(p = 0.0237) by 22.8%, 18.4% and 17.3% respectively, after
atorvastatin treatment alone. Conversely, there was an
increased effect in levels of TC (p = 0.743) by 1.7%, nonHDL-c (p = 0.075) by 14.5%, LDL-c (p = 0.022) by 21.5%
and CR (p = 0.955) by 0.5% after atorvastatin treatment
(Table 6).

Table 1 Socio-demographic characteristics of study participants: Baseline and follow up
Variable

Total

Baseline (n = 240)

Follow up (n = 160)

X2, df

p value

Age (years)

57.80 ± 10.63

57.82 ± 10.88

57.79 ± 10.39

0.370t

0.981

26.80 ± 9.44

26.13 ± 5.11

27.47 ± 13.78

1.367t

0.172

1.090t

0.276

17.5, 3

0.002

3.01, 4

0.55

39.65, 3

0.0001

25.22, 1

0.0001

Male:female ratio
BMI (Kg/m2)
WHR

165/236

99/142

66/94

0.93 ± 0.05

0.93 ± 0.06

0.92 ± 0.05

Married

269 (67.1)

164 (68.0)

105 (65.6)

Never married

6 (1.5)

4 (1.7)

2 (1.3)

Divorced

41 (10.2)

25 (10.4)

16 (10.0)

Widowed

85 (21.2)

48 (19.9)

37 (23.1)

Tertiary

58 (14.5)

36 (14.9)

22 (13.8)

Senior high school

104 (25.9)

57 (23.7)

47 (29.4)

Junior high school

133 (33.2)

78 (32.4)

55 (34.4)

Lower primary

43 (10.7)

28 (11.6)

15 (9.4)

No formal education

63 (15.7)

42 (17.4)

21 (13.1)

Employed

229 (57.1)

133 (55.2)

96 (60.0)

Retired

85 (21.2)

35 (14.5)

50 (31.1)

Unemployed

65 (16.2)

51 (21.1)

14 (8.8)

Informal employment

22 (5.5)

21 (9.0)

1 (1)

Primarily sedentary

101 (25.2)

79 (32.8)

22 (13.8)

Moderate activity

300 (74.6)

162 (67.2)

138 (85.5)

Marital status

Education

Occupation

Physical activity

Values are presented as frequency (percentage); mean ± SD
t

t-test value
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Table 2 Distribution of clinical characteristics among study participants
Variables

Total

Baseline (n = 241)

Follow-up (n = 160)

24 (6.0)

14 (5.8)

10 (6.3)

Age
31–40
41–50

76 (19.0)

49 (20.3)

27 (16.9)

51–60

136 (33.9)

81 (33.6)

55 (34.4)

61–70

118 (29.4)

68 (28.2)

50 (31.3)

71–80

47 (11.7)

29 (12.0)

18 (11.3)

11 (2.8)

9 (3.80)

2 (1.30)

BMI
Underweight
Normal weight

175 (43.9)

170 (44.6)

68 (42.8)

Overweight

132 (33.10)

80 (33.3)

52 (32.7)

Obese

81 (20.3)

44 (18.3)

37 (23.3)

Normal

121 (55.1)

132 (54.8)

89 (55.6)

High

180 (44.9)

109 (45.2)

71 (44.4)

Normal

298 (74.5)

177 (73.8)

121 (75.6)

High

102 (25.5)

63 (26.3)

39 (24.4)

Normal

104 (26.0)

74 (30.8)

30 (18.8)

High

296 (74.0)

166 (69.2)

130 (81.3)

Normal

160 (39.9)

94 (39.0)

66 (41.3)

High

241 (60.1)

147 (61.0)

94 (58.8)

Good

343 (86.2)

199 (82.6)

144 (91.7)

High

55 (13.8)

42 (17.4)

13 (8.3)

Good

259 (65.2)

154 (64.2)

105 (66.9)

High

138 (34.8)

86 (35.8)

52 (33.1)

Good

235 (59.0)

189 (78.4)

46 (29.3)

Low

163 (41.0)

52 (21.6)

111 (70.7)

Normal

188 (47.4)

117 (48.8)

71 (45.2)

High

209 (52.6)

123 (51.3)

86 (54.8)

164 (41.3)

106 (44.2)

58 (36.9)

SBP

DBP

HbA1c

FPG

TG

TC

HDL

NonHDL

LDL
Good
High
SBP (mmHg)
DBP (mmHg)
FBS (mmol/l)
HbA1c (mmol/l)
TC (mmol/l)
TG (mmol/l)
HDL-c (mmol/l)
Non-HDL-c (mmol/l)
LDL-c (mmol/l)
Coronary risk
VLDL-c (mmol/l)

X2, df

p value

0.909, 4

1.000

3.386, 3

0.336

0.028, 1

0.474

0.178, 1

0.382

7.280, 1

0.004

0.202, 1

0.364

6.679, 1

0.006

0.308, 1

0.328

94.80, 1

<0.0001

0.474, 1

0.270

2.040, 1

0.092

233 (58.7)

134 (55.8)

99 (63.1)

140.06 ± 24.09

139.41 ± 24.31

140.71 ± 23.88

0.525t

0.600

0.484t

0.620

18.32 ± 4.31

9.18 ± 4.42

82.28 ± 12.65
9.14 ± 4.20

0.082t

0.940

9.32 ± 2.88

4.201t

0.0001

4.54 ± 1.27

1.406t

0.160
0.0001

81.96 ± 13.18
8.79 ± 2.49

4.63 ± 1.27

81.63 ± 13.71
8.27 ± 2.10

4.73 ± 1.27

1.17 ± 0.56

1.27 ± 0.57

1.07 ± 0.56

3.520t

3.44 ± 1.22

3.37 ± 1.24

3.52 ± 1.20

1.19 ± 1.19

1.35 ± 1.35

1.03 ± 1.03

9.960t

0.0001

1.142t

0.250

2.91 ± 0.57

2.79 ± 1.16

3.03 ± 1.13

2.029t

0.430

0.232t

0.820

0.54 ± 0.33

0.58 ± 0.26

0.51 ± 0.41

1.965t

0.500

5.00 ± 2.7

4.97 ± 1.52

5.04 ± 3.88
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Table 3 Association between metabolic risk factors and FBG levels at baseline and follow up
Variables

X2, df (p value)

FBG (baseline)
High (n = 147)

Normal (n = 94)

aOR (95% CI)

Male

56 (38.1)

43 (45.7)

1.0#

Female

91 (61.9)

51 (54.3)

1.37 (0.81–2.32)

Gender

Underweight

X2, df (p value)

FBG (follow up)
High (n = 94)

Normal (n = 66)

aOR (95% CI)

33 (35.1)

33 (50.0)

1.0#

61 (64.9)

33 (50.0)

1.85 (0.97–3.51)

1.38, 1 (0.239)

BMI
Normal

p value

3.55, 1 (0.06)
0.283

2.18, 3 (0.537)
6 (4.1)

3 (3.2)

70 (47.9)

37 (39.4)

1.05 (0.25–4.47)

p value

0.073

1.77, 3 (0.622)
1.000

1.0#

2 (2.1)

1 (1.5)

40 (42.6)

28 (43.1)

1.40 (0.12–16.21)

1.000

1.0#

Overweight

46 (31.5)

34 (36.2)

0.72 (0.39–1.29)

0.289

29 (30.9)

23 (35.4)

0.88 (0.43–1.83)

0.852

Obese

24 (16.4)

20 (21.3)

0.63 (0.31–1.30)

0.268

23 (24.5)

14 (21.5)

1.15 (0.51–2.62)

0.836

Normal

77 (52.4)

55 (58.5)

1.0#

49 (52.1)

40 (60.6)

1.0#

High

70 (47.6)

39 (41.5)

1.28 (0.76–2.16)

45 (47.9)

26 (39.4)

1.41 (0.75–2.68)

SBP

0.87, 1 (0.351)

DBP

1.13, 1(0.288)
0.357

0.02, 1 (0.901)

Normal

108 (73.5)

69 (74.2)

1.0#

High

39 (26.5)

24 (25.8)

1.04 (0.57–1.88)

TC

1.000

67 (73.1)

54 (81.8)

1.0#

27 (28.7)

12 (18.2)

1.81 (0.84–3.91)

0.22, 1 (0.642)

Good

92 (63.0)

62 (66.0)

1.0#

High

54 (37.0)

32 (34.0)

1.14 (0.67–1.96)

TG
Good

120 (81.6)

79 (84.0)

1.0#

27 (18.4)

15 (16.0)

1.19 (0.59–2.37)

HDL-c

0.681

62 (66.0)

43 (68.3)

1.0#

32 (34.0)

20 (31.7)

1.11 (0.56–2.19)

Good

115 (78.2)

74 (78.7)

1.0#

32 (21.8)

20 (21.30)

1.03(0.55–1.93)

Non-HDL

85 (90.4)

59 (93.7)

9 (9.6)

4 (6.3)

0.729

Normal

72 (49.3)

45 (47.5)

1.0#

74 (50.7)

49 (52.1)

0.94 (0.56–1.59)

LDL-c

1.000

25 (26.6)

21 (33.3)

1.0#

69 (73.4)

42 (66.7)

1.38 (0.69–2.77)

68 (46.6)

38 (40.4)

1.0#

High

78 (53.4)

56 (59.6)

0.78 (0.46–1.32)

0.565

0.377

0.24,1 (0.621)
0.895

41 (43.6)

30 (47.6)

1.0#

53 (56.4)

33 (52.4)

1.18 (0.62–2.23)

0.88, 1 (0.349)

Good

1.0#
1.56 (0.46–5.31)
0.83,1 (0.363)

0.05, 1 (0.827)

High

0.863

0.52,1 (0.472)

0.01, 1(0.928)

Low

0.139

0.09, 1 (0.764)

0.23, 1(0.630)

High

0.333

2.34, 1(0.126)

0.628

0.84,1 (0.358)
0.355

32 (34.0)

26 (41.3)

1.0#

62 (66.0)

37 (58.7)

1.36 (0.71–2.63)

0.401

Logistic regression model, adjusted for age and medication. 1.0#: reference point for odds ratio
X2, df Chi square value, degrees of freedom, aOR adjusted odds ratio, CI confidence interval

For non-hypertensive T2DM participants, there
was no significant change in SBP and DBP from baseline to follow up (Table 7). SBP levels were reduced by
0.1% after CCB + ACEI treatment (p = 0.969). Levels
of both SBP and DBP were reduced by 1.9% (p = 0.644)
and 5.8% (p = 0.128) respectively after ACEI treatment alone and decreased by 1.0% (p = 0.835) and 0.1%
(p = 0.912) respectively after CCB + ARB combination therapies. However, levels of both SBP and DBP
increased by 3.0% (p = 0.683) and 0.4% (p = 0.942)
respectively after CCB treatment alone and increased
by 17.3% (p = 0.061) and 11.3% (p = 0.086) respectively
after CAD treatment alone, while a combination therapy of CCB + ACEI increased DBP by 1.9% (p = 0.666)
(Table 7).

Discussion
The prevalence of T2DM has increased tremendously in
the past few decades among different countries worldwide [2, 3, 31–34]. SSA remains one of the most affected
regions due to rapid urbanisation and increased adoption
of a westernised diet with less physical activity [5, 30–34].
In this hospital-based study, we examined the major
factors that characterise T2DM and how these factors
influence anti-diabetes medication response. As reported
by Danquah et al. [5], the majority of T2DM patients in
urban Ghana are middle aged, of low socio-economic status and their lifestyle is primarily sedentary [5]. Moreover, our findings on clinical parameters such as SBP, DBP,
HDL-c, LDL-c, TG, TC and FBG are similar to those
reported in their study [5].

Adua et al. Clin Trans Med (2017) 6:32

Page 7 of 11

Table 4 Association between metabolic risk factors and HbA1c levels at baseline and follow up
Variables

X2, df (p value)

HbA1c (baseline)
Poor (n = 167)

Good (n = 74)

aOR (95% CI)

Gender
67 (40.4)

32 (43.2)

1.0#

Female

99 (59.6)

42 (56.8)

1.13 (0.65–1.96)

BMI

X2, df (p value)

Poor (n = 130)

Good (n = 30)

aOR (95% CI)

56 (43.1)

10 (33.3)

1.0#

74 (56.9)

20 (66.7)

0.66 (0.29–1.52)

5 (3.0)

4 (5.4)

Normal

77 (46.7)

30 (40.5)

1.0#

Overweight

53 (32.1)

26 (35.1)

0.79 (0.42–1.49)

Obese

30 (18.2)

14 (18.9)

0.83 (0.39–1.79)

SBP

0.49 (0.12–1.94)

0.673

86 (51.8)

46 (62.2)

1.0#

High SBP

80 (48.2)

28 (37.8)

1.53 (0.87–2.68)

DBP

0.445

2 (1.6)

0 (0.0)

56 (43.4)

12 (40.0)

0.519

45 (34.90

7 (23.3)

1.38 (0.50–3.78)

0.619

0.695

26 (20.2)

11 (36.7)

0.50 (0.19–1.29)

0.216

55 (75.3)

1.0#

45 (27.1)

18 (24.7)

1.14 (0.60–2.14)

TC

0.161

74 (56.9)

15 (50.0)

1.0#

56 (43.1)

15 (50.0)

0.76 (0.34–1.68)

101 (61.2)

53 (71.6)

1.0#

High

64 (38.8)

21 (28.4)

1.60 (0.88–2.89)

TG

0.752

98 (75.4)

23 (76.7)

32 (24.6)

7 (23.3)

Good

137 (82.5)

61 (82.4)

1.0#

29 (17.5)

13 (17.6)

0.99 (0.48–2.04)

HDL-c

0.144

84 (65.6)

21 (72.4)

44 (34.4)

8 (27.6)

132 (79.0)

57 (77.0)

1.0#

Low

35 (21.0)

17 (23.0)

0.90 (0.46–1.73)

Non-HDL

1.000

119 (93.0)

25 (86.2)

9 (7.0)

4 (13.8)

79 (47.9)

38 (51.4)

1.0#

High

86 (52.1)

36 (48.6)

1.15 (0.66–1.99)

LDL-c

0.737

39 (30.5)

7 (24.1)

89 (69.5)

22 (75.9)

74 (44.8)

32 (43.2)

1.0#

High

91 (55.2)

42 (56.8)

0.94 (0.54–1.630

0.522

1.0#
0.47 (0.14–1.68)

0.262

1.0#
0.73 (0.29–1.84)

0.652

0.002, 1 (0.962)
0.675

58 (45.3)

13 (44.8)

1.0#

70 (54.7)

16 (55.2)

0.98 (0.44–2.21)

0.05,1 (0.817)

Good

1.0#
1.38 (0.56–3.36)

0.46, 1 (0.499)

0.25, 1 (0.620)

Normal

1.000

1.42, 1 (0.233)

0.11, 1 (0.743)

Good

1.0#
1.07 (0.42–2.73)
0.49, 1 (0.483)

0.00, 1 (0.985)

High

0.544

0.022, 1 (0.883)

2.42, 1 (0.12)

Good

1.0#

0.47, 1(0.491)

0.16, 1 (0.692)
121 (72.9)

0.413

4.38, 3 (0.224)

2.22,1 (0.136)

Normal

p value

0.96, 1 (0.328)

1.35, 3 (0.718)

Underweight

High DBP

HbA1c (follow-up)

0.18, 1 (0.675)

Male

Normal

p value

1.000

0.53,1 (0.465)
0.888

49 (38.3)

9 (31.0)

79 (61.7)

20 (69.0)

1.0#
0.73 (0.31–1.72)

0.528

Logistic regression model, adjusted for age and medication. 1.0#: reference point for odds ratio
X2, df Chi square value, degrees of freedom, aOR adjusted odds ratio, CI confidence interval

Table 5 Utilisation of glucose lowering medications among T2DM patients
Baseline

Follow up

Mean difference (95% CI)

p value

% effect

Treatment
FBG (mmol/l)
  BIG only
  BIG + SUA

  BIG + TNZ

  BIG + SUA + TNZ

HbA1c (%)
  BIG only

  BIG + SUA

  BIG + TNZ

  BIG + Sul + TNZ

8.02 ± 0.65

8.45 ± 0.49

9.63 ± 0.59

9.921 ± 0.66
7.34 ± 0.28

8.11 ± 0.32

8.68 ± 0.33

8.46 ± 0.26

BIG Biguanide, SUA Sulfonylurea, TNZ Thiazolidinedione
p < 0.05 is considered significant

2.05 (−1.25 to 5.36)

0.2162

25.00

8.441 ± 0.82

10.08 ± 1.12

−0.01 (−1.83 to 1.82)

0.9924

−0.10

8.36 ± 1.04

−1.57 (−4.06 to 0.93)

11.88 ± 1.47

9.51 ± 1.10

9.67 ± 0.65

10.12 ± 1.04
8.57 ± 0.47

2.25 (−0.52 to 5.02)

0.1098
0.216

23.40

−15.80

2.17 (0.57 to 3.78)

0.0094

29.60

1.55 (0.28 to 2.83)

0.0175

19.20

1.45 (−0.23 to 3.14)

0.0903

16.70

0.11 (−0.91 to 1.12)

0.8308

1.30
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Table 6 Utilisation of lipid lowering medications among T2DM patients
Variable

Baseline

Follow up

Mean difference (95% CI)

4.95 ± 0.13

−0.07 (−0.42 to 0.28)

p value

% difference

TC (mmol/l)
No statin
Atorvastatin
TG (mmol/l)
No statin
Atorvastatin
HDL-c (mmol/l)
No statin
Atorvastatin
Non-HDL (mmol/l)
No statin
Atorvastatin
LDL-c (mmol/l)
No statin
Atorvastatin
CR
No statin
Atorvastatin
VLDL-c (mmol/l)
No statin
Atorvastatin

5.03 ± 0.12

4.06 ± 0.16

4.13 ± 0.16

1.32 ± 0.06

1.19 ± 0.06

0.6817

1.39

0.07 (−0.37 to 0.51)

0.7434

1.72

−0.13 (−0.30 to 0.04)

0.1322

9.85

1.14 ± 0.06

0.93 ± 0.06

−0.21 (−0.39 to −0.03)

0.0259

18.42

1.36 ± 0.03

1.05 ± 0.03

−0.30 (−0.39 to −0.21)

<0.0001

22.06

<0.0001

22.79

1.36 ± 0.04

1.04 ± 0.04

3.67 ± 0.11

−0.31 (−0.42 to −0.19)

3.89 ± 0.12

2.69 ± 0.15

3.09 ± 0.15

3.06 ± 0.11

3.36 ± 0.11

2.19 ± 0.15

2.68 ± 0.14

5.24 ± 0.15

5.57 ± 0.49

4.31 ± 0.19

4.32 ± 0.20

0.60 ± 0.03

0.58 ± 0.05

0.52 ± 0.03

0.42 ± 0.03

0.23 (−0.09 to 0.55)

0.1617

6.27

0.39 (−0.04 to 0.81)

0.0754

14.50

0.30 (−0.01 to 0.60)

0.058

9.80

0.47 (0.06 to 0.87)

0.022

21.46

0.33 (−0.68 to 1.34)

0.5202

6.29

0.02 (−0.53 to 0.57)

0.9547

0.46

−0.01 (−0.12 to 0.09)

0.8181

−0.09 (−0.18 to −0.01)

1.67
17.3

0.0237

CI confidence interval
p < 0.05 is considered significant

Table 7 Utilisation of anti-hypertensive medicines among T2DM patients
Anti-hypertensive drugs

Baseline

Follow up

Mean difference (95%CI)

p value

%effect

SBP (mmHg)
DM only (n = 38)

127.1 ± 4.09

130.5 ± 3.45

3.34 (−7.33 to 14.01)

0.534

2.63

CCB (n = 11)

150.2 ± 7.99

154.6 ± 7.21

4.46 (−18.02 to 26.92)

0.683

2.96

0.01 (−10.74 to 10.74)

>0.999

0.00

0.644

−1.90

DM + HPT

ARB (n = 22)

ACEI (n = 30)

CAD (n = 8)

CCB + ARB (n = 24)

CCB + ACEI (n = 27)
DM only (n = 38)

DM + HPT

CCB (n = 11)

ARB (n = 22)

ACEI (n = 30)

CAD (n = 8)

CCB + ARB (n = 24)

CCB + ACEI (n = 27)

130.1 ± 3.04

130.4 ± 3.93

150.6 ± 9.07

153.3 ± 5.74

130.0 ± 4.36

128.0 ± 3.59

−2.47 (−13.12 to 8.19)
26.0 (−2.43 to 54.43)

0.061

151.7 ± 4.98

−1.58 (−16.88 to 13.72)

0.835

1.03

176.6 ± 8.33

17.30

143.1 ± 3.33

142.9 ± 3.46

−0.19 (−9.83 to 9.46)

0.969

0.13

74.87 ± 2.25

77.87 ± 1.80

3.00 (−2.75 to 8.74)

0.301

4.00

DBP (mmHg)

83.18 ± 3.74

80.00 ± 2.31

80.01 ± 1.89

93.80 ± 5.23

86.13 ± 3.33

82.81 ± 2.78

83.55 ± 3.23

80.02 ± 2.09

0.36 (−9.95 to 10.68)

0.942

0.43

1.00 (−5.29 to 7.30)

0.750

1.25

76.43 ± 2.37

−4.67 (−10.73 to 1.40)

86.08 ± 2.62

−0.04 (−8.58 to 8.50)

104.4 ± 7.22

84.41 ± 2.40

10.6 (−9.96 to 31.16)

1.59 (−5.78 to 8.96)

0.128

5.76

0.086

11.30

0.992

0.05

0.666

1.92

CCB calcium channel blockers, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin II receptor blockers, CADcentral acting drugs
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Overall, several of these biomarkers are higher than the
recommended threshold for T2DM as suggested by the
WHO and the ADA [35, 36]. For example, approximately
60 and 69.2% of the participants were not able to achieve
the desired FBG and HbA1c targets respectively. This is
in fact disturbing given the direct association between
abnormal plasma glucose levels and macrovascular or
microvascular complications. Efforts to control glucose
levels are necessary and could be achieved in several
ways. After diagnosis, medical nutrition therapy (MNT)
is necessary to reduce weight and normalise glucose levels [37].
However, it has been established that MNT alone is not
sufficient for improving plasma glucose levels. As such,
the use of medications becomes the next phase of action
[37].
In Ghana, several glucose lowering medications have
been approved for the treatment of hyperglycaemia
including SUAs, TNZs and biguanides, the latter being
the first line anti-diabetic medicine [5]. Like many other
countries, its popularity is because: (1) it is less expensive,
(2) it is effective for weight reduction and plasma glucose
levels, and (3) it has a reduced risk for hypoglycaemia
[38]. Not surprisingly, a high proportion of our participants (>80%) were on this medication, most of whom
had used this drug for a period long before the start of
this study. However, the majority of those who used BIG
(metformin) alone could not achieve the desired glycaemic level even at follow up although there seems to be a
minimal percentage effect (29.6%, p = 0.0094) on HbA1c
level (Tables 3, 4, 5). This emphasises the failure of metformin as a monotherapy to achieve glucose control. At
this point, the focus shifts towards individuals undergoing combination and multiple therapies.
SUAs and TNZs have been recognised as second line
anti-diabetic medications and their efficacy is similar to
metformin [25, 38]. However, it was apparent after six
months that even with multiple therapies, the majority
of the patients could not attain the desired glucose target
levels. Only a minimal percentage effect of BIG + SUA
(19.2%, p = 0.0175) on HbA1c was observed (Table 5).
Several reasons can be attributed to this:
Firstly, there is a possibility of poor adherence to oral
medications, especially among those taking combination and multiple therapies, not only for hyperglycaemia
but also for other comorbidities [26, 38, 39]. Moreover,
many of these drugs are associated with side effects and
hence it is possible that some participants will be selective in their choice of medicine (Additional file 1: Table
S1). In a study among 2849 T2DM patients in the UK, it
was shown that only 13% of the patients adhered strictly
to the drug regimen [40]. This could possibly be the case
in our study as some participants may have become bored
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with swallowing different medications daily. Efforts to
simplify treatment regimens should therefore be intensified. For example, instead of multiple medications, singledose combination pills with minimal side effects could
be administered. Secondly, ensuring adequate control of
glycaemic status requires a paradigm shift from sedentary
behaviour to a more physically active lifestyle. One study
has shown that moderate-intensity physical activity such
as brisk walking and reducing time spent watching television to less than 30 min per day could reduce several
modifiable T2DM risk factors including plasma LDL-c
and TG while increasing HDL-c [41]. A meta-analysis also
showed that physical activity is inversely associated with
risk for T2DM [42].
Moreover, intense exercise is necessary to stimulate 5-adenosine monophosphate-activated kinase
(5-AMPK) causing the release of glucose to the muscles rather than it accumulating in the plasma [4]. In
our study however, we were unable to assess the level or
intensity of physical activity by the individuals. Therefore, an effective physical assessment tool such as the
international physical activity questionnaire (IPAQ)
could be useful [43].
Thirdly, poor dietary preferences may have been a contributory factor. Studies have shown that healthy diets or
consumption of vegetables, low calorie diets, low trans
fats, legumes, fruits, poultry, whole grains and cereal
fibre is linked to a reduced risk of metabolic syndrome
and T2DM [44, 45]. Conversely, consumption of red and
processed meat, sugar-sweetened beverages, desserts and
fried foods is associated with an increased risk of T2DM
[44, 45]. However, whether or not the majority of the
study participants utilised a particular food was unverified and therefore, a validated food frequency questionnaire would also have been useful.
Despite the increasing use of anti-hypertensives, BP
control was suboptimal in our study population. With
an attrition rate of nearly 40%, only 52 T2DM participants who took anti-hypertensive medications were able
to maintain a target BP (both SBP and DBP) at follow up
(Table 7). Majority were unable to achieve a desired target although they took more than one antihypertensive
drug. This is disturbing given that high BP is by far the
most critical risk factor for cardiovascular disease (CVD)
and stroke [46]. Other studies that have explored the role
of intensive BP control in preventing CVD have produced conflicting results. One study showed that a DBP
of ≤80 mmHg could reduce the risk of CVD by 50% [47].
However, another study reported that SBP ≤120 mmHg
was not associated with a reduced risk for CVD [48].
Notwithstanding this, our findings agree with several
other studies that BP is poorly controlled among T2DM
patients worldwide [49, 50].
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Statins are well-known lipid lowering medications and
the common one used by participants in this study is atorvastatin. More than half of the participants taking atorvastatin had good lipid profiles and this is consistent with the
findings by Wong et al. [39]. Moreover, our study showed
that there was a significant improvement in several lipid
markers such as TG, LDL-c, HDL-c and VDL-c at follow
up (Table 6). Whether atorvastatin interfered with glucose
homeostasis is yet to be determined but our study confirms
that atorvastatin is a potent drug for treating dyslipidaemia.
The present study does have some limitations. Firstly,
because it was an observational longitudinal study, it was
limited by confounding factors such as differences in dosage regimen. Dosage regimen refers to the modality of drug
administration/doses per unit of time to reach a therapeutic
objective. This comprises the time or frequency when the
drug should be administered, the time between doses and
the amount or unit dose of medicine to be administered at
a specific time [51–53]. However, given the number of participants, each with a different medication dosage at a point
in time, it was difficult to take into consideration the dosage
regimen. At the same time, certain tests especially FBG are
influenced by biological variation even when fluoride tubes
are used. For example, stressful situations in the hours preceding FBG test could increase FBG levels [54]. Thus, we
were unable to provide a full explanation on the poor drug
response among some participants. Secondly, a clinical randomised control trial would have eliminated potential confounding factors, and also shed further light on the effect of
the various medications in lowering modifiable risk factors.
Thirdly, the sample size of the study was small and therefore
cannot be representative of the entire T2DM population.
Finally, over 40% of the participants were lost to follow up
and this may have had an effect on our assessments.

Conclusion
Our study showed that the use of statins is effective for
improving lipid profiles and can be regarded as a potent
medication for treating dyslipidaemia. However, utilisation of oral hypoglycaemic agents whether as a monotherapy, combination or polytherapy was not effective for
achieving plasma glucose targets of <7%. This is alarming
and therefore, alternative approaches including a less sedentary lifestyle while engaging in vigorous exercise may
reduce weight and obesity; enforcing healthy eating practices and administration of single/fixed-dose combination tablets or pills with minimal side effects may improve
medication adherence (Additional file 1: Table S1).
Additional file
Additional file 1: Table S1. Morisky adherence scale-8 (MMAS-8).
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